Clinical trial

Clinical Study to Assess Therapeutic Delay and Resolution of Induced Gingivitis

Name
CRO-2018-07-IND-GING-DELAY-JG
Description
Evaluate a stannous technology for its effect on the neutrophil phenotype during an induced gingivitis state.
Trial arms
Trial start
2018-12-22
Estimated PCD
2020-12-22
Trial end
2020-12-22
Status
Completed
Phase
Early phase I
Treatment
Stannous Fluoride Toothpaste
0.454% stannous fluoride toothpaste
Arms:
Stannous fluoride test toothpaste
Other names:
Colgate Total SF
Colgate fluoride toothpaste
0.76 % Sodium MonoFluorophosphate (MFP)
Arms:
Colgate flouride toothpaste
Other names:
Colgate Dental Cream
Size
26
Primary endpoint
Bleeding Index (BOP) and Oral Inflammatory Load
during patient visit over the 9 weeks
Eligibility criteria
Inclusion Criteria: 1. Male or female volunteers aged 18-70 years 2. In good general health, ASA I 3. No clinical signs of gingival inflammation at \>90% sites observed 4. Probing Depth (PD) \< 3.0 mm 5. Attachment Loss (AL) = 0 mm 6. No periodontal disease history 7. Non-smokers 8. Fluent in English Exclusion Criteria: 1. Presence of orthodontic bands. 2. Presence of partial removal dentures. 3. Tumour(s) of the soft or the hard tissues of the oral cavity. 4. Cavitated carious lesions requiring immediate restorative treatment. 5. History of allergy to consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study. 6. Participation in any other clinical study or test panel with a one month period prior to entering the study.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 26, 'type': 'ACTUAL'}}
Updated at
2023-02-16

1 organization

2 products

1 indication

Indication
Gingivitis
Product
Colgate
Organization
Colgate-Palmolive